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Abstract: The superiority of transcatheter aortic valve replacement (TAVR) compared with medical therapy for 
patients with aortic stenosis (AS) who are not suitable candidates for surgery had been proven. Cardiopulmonary 
bypass (CPB) is rarely used in TAVR. Reports of early use of extracorporeal membranous oxygenator (ECMO) have 
promising outcomes. ECMO offers the option of cardiac support rescue in case of intraoperative hemodynamic 
instability and can be instituted in advance when hemodynamic instability is expected. Here we review the English 
literature about the use of ECMO in TAVR procedures, and discuss the indications and rationale for its use as well 
as its advantages.
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Introduction
Aortic stenosis (AS) is the most common form of valvular 
heart disease that predominantly affects elderly patients. 
Its prevalence is estimated at 4.6% in patients greater than 
75 years of age (1). Patients with severe AS who develop 
symptoms have a very poor prognosis with significant 
decrease in survival and a 50% mortality within 2 years 
without treatment (2). The operative risk is elevated 
during conventional aortic valve replacement with a 
mortality ranging up to 30% in patients with advanced 
heart failure (3-6). After the introduction of transcatheter 
aortic valve replacement (TAVR) by Cribier et al. (7) in 
2002, the superiority of TAVR compared with medical 
therapy for patients considered too high risk for surgery 
has been established. TAVR has become more attractive 
as the appropriate alternative for elderly patients with very 
high surgical risk (4,5,8-11). Considering the prognosis of 
patients who are not candidates for TAVR nor conventional 
aortic valve replacement have mortality rate at 6 months 
is 31.8% and at 2 years 53.4% (6,12), Leon et al. and 
Reiss et al. (13,14) concluded in the PARTNER trial that 
“TAVR should be the new standard of care for patients with AS 
who are not suitable candidates for surgery”. Nowadays, TAVR 
continues to grow beyond those populations originally 
studied, to include those with severe left ventricular 
dysfunction and those with failing surgical homografts 
(valve-in-valve TAVR) (15,16). Although, TAVR expands 
the options for patients with severe AS and is less-
invasive alternative in high-risk frail and decompensated 
patients, it remains a complex procedure that may result 
in serious complications (e.g., severe aortic regurgitation, 
major bleeding, device embolization, coronary occlusion, 
and aortic dissection). While these complications are 
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uncommon, they may precipitate sudden hemodynamic 
collapse necessitating cardiopulmonary bypass (CPB) or 
other mechanical support (17,18).
Use of CPB in TAVR procedures
Mechanical circulatory support (MCS) devices were used 
in nearly 10.6% of the patients who underwent TAVR 
procedures, among these CPB was used between 1.2% to 
6.6% of TAVR cases (8,18,19). Drews et al. (20), however, 
reported increase of the CPB use to 13% of these very high-
risk patients during valve implantation. It also has been 
shown that using MCS in TAVR procedures was associated 
with significantly high rates of mortality, complications, 
and increased length and cost of hospitalization (8). The use 
of MCS was also identified as an independent predictor of 
increased early and late mortality (21). Furthermore, it was 
also reported that CPB recipients had the highest 1-year 
mortality rate compared to patients who required intra-
aortic balloon pump (IABP) and no support at all: 1-year 
mortality rate was 52.8% in those who received MCS 
emergently versus planned MCS of 40.3% versus no MCS 
of 21.6% (19).
Not all patients electively put on CPB during the 
procedure need the support. However, elective CPB should 
be considered in patients with severe cardiogenic shock, 
poor left ventricular function, or enlarged right ventricle 
with severe pulmonary hypertension (20). Its elective use 
will increase the safety in critically ill patients in order 
to maintain hemodynamic stability during the phases of 
rapid pacing and to eliminate manual cardiopulmonary 
resuscitation as the postoperative course of these patients is 
unfavorable (20).
CPB is also used as an intraoperative emergent method to 
rescue patients from myocardial collapse as a consequence 
of the most severe TAVR complications and allows time to 
perform a thorough diagnostic evaluation and facilitate a safe 
definitive treatment of the complication (18). Intraoperative 
emergent complications needing CPB might include severe 
paravalvular leak in patients with depressed left ventricular 
function, severe diastolic dysfunction, or significant mitral 
regurgitation. The ability of these patients to compensate 
for acute severe aortic insufficiency may be compromised 
(22-25). The use of CPB allows time for a full assessment 
of the leak and either re-ballooning of the prosthesis or 
preparation of a second device for valve-in-valve treatment. 
CPB also can be used in cases of coronary malperfusion, 
or severe bleeding at the apex of the left ventricle which 
allows decompression of the ventricle to facilitate a safe 
primary repair. The hemodynamic support provide by 
CPB is not without potential harm as it is well documented 
in the literature that CPB is associated with undesirable 
side effects, e.g., activation of inflammatory mediators, 
increased pulmonary vascular resistance, platelet activation, 
coagulopathy and impaired renal function (26-29).
Use of extracorporeal membranous oxygenator 
(ECMO) as an alternative to CPB in TAVR 
procedures
The advances in ECMO technology and the improvement 
of commercially available percutaneous cannulas of different 
sizes and lengths in the complete implantation sets make 
ECMO at present day a more powerful resuscitation tool 
(30,31). It is also relatively less expensive than some forms of 
MCS (32). Additionally, it is easier to transport the patient 
with ECMO support or to use it bedside if necessary. 
Miniaturized ECMO systems can be highly effective 
and safe for the initiation of emergency ECMO while 
performing cardiopulmonary resuscitation (e-CPR) in the 
cardiac catheterization laboratories. Especially for patients in 
need of cardiac surgery, transfer to extracorporeal assistance 
can be more easily processed by using miniaturized ECMO 
systems (30). Furthermore, ECMO provides both cardiac 
and pulmonary support for patients for some duration 
until they recover from the complications or a decision is 
made for definite operative plans. The unit can also provide 
mild hypothermia for cerebral protection in the event of 
complete prolonged hemodynamic collapse (33). 
Use of ECMO as emergency rescue
Along with some case reports regarding using ECMO as 
emergency rescue (34-36), there are four papers (22-24,30) 
reporting series of multiple patients these are listed in 
Table 1 (1), in these series the using of ECMO permitted 
to procedure completion in 44–66%, support to surgery in 
33–56% and survival to discharge in 44–75% of cases. Over 
all in the cohort study published by Husser et al. (22): the 
veno-arterial extracorporeal membrane oxygenation (VA-
ECMO) cohort was significantly higher risk (median logistic 
EuroSCORE 26% vs. 15%). They concluded that emergent 
implantation of VA-ECMO for circulatory support appears 
to be safe and feasible to stabilize the patient for further 
treatment (22). Both Seco et al. and Husser et al. concluded 
that VA-ECMO may potentially minimize the effect of 
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TAVR complications (22,23). Most common reasons for 
emergent peri-procedural initiation of ECMO were: (I) 
ventricular perforation; (II) hemodynamic instability; 
(III) refractory cardiogenic shock; and (IV) hemodynamic 
deterioration due to ventricular arrhythmia. 
These outcomes are comparable to the literature about 
using CPB for emergency support of intraoperative TAVR 
complication. Eggebrecht et al. (37) reported 12 patients 
(4%) of their series required emergent CPB; all 4 needed 
surgical conversion with a resulting 30-day survival of 52%. 
Roselli et al. (18) also reported a single-centre series, 12 (4%) 
of 303 patients undergoing TAVR required emergency CPB 
following complications resulting in hemodynamic collapse. 
In three patients a period of resuscitation with CPB was 
sufficient for recovery, while nine required complication-
specific procedures (e.g., valve-in-valve TAVR, conversion 
to open procedure and SAVR). Seven patients required 
additional circulatory support, five via IABP, and two via 
VA-ECMO. Thirty-day mortality was 16% with only 45% 
survival at 12 months. This is far lower survival than in 
TAVR patients not requiring emergency CPB (19).
Use of ECMO as prophylactic measure
There is little in the literature reported about using 
prophylactic support with VA-ECMO with only two papers 
(22,23) reporting series of multiple patients. These are 
listed in Table 2. In a cohort study about ECMO use in nine 
TAVR patients, the authors noted that preemptive use of 
ECMO in selected high risk patients was associated with 
improved procedural success (100%) and 30-day survival 
to discharge of 100%. They concluded that prophylactic 
strategy may be suitable in the following scenario: severely 
impaired left ventricular function, slow recovery from rapid 
left ventricular pacing during testing of a pacemaker, high 
vasopressor requirements during general anesthesia or 
concomitant high risk PCI (22). Seco et al. (23) reported 
the same results in their series of eight patients. These 
outcomes are also comparable to the published data 
about using CPB in patients of very high risk (logistic 
EuroSCORE 59%, STS 35%). Overall technical success 
(94%) and peri-procedural complications were comparable 
to the standard TAVR cohort, suggesting planned ECMO 
may be a feasible adjunct in high-risk cases that may 
otherwise have been declined TAVR (20).
Given that  TAVR pat ients  are  often fra i l  and 
decompensated, early signs of hemodynamic instability 
during anesthetic induction may be predictive of subsequent 
problems and dictate additional measures to be initiated for 
stabilization (38). 
Conclusions
The outcomes of using ECMO as prophylactic are 
Table 1 Emergency use of ECMO
Study






Support to  
surgery
Survival to  
discharge (%)
Husser et al. (22) 131 9 (7%) 4 (44%) 5 (56%) 44
Seco et al. (23) 100 3 2 (66%) 1 (33%) 66
Banjac et al. (24) 230 10 (4.3%) – 5 (50%) 70
Arlt et al. (30) 4 2 (50%) 2 (50%) 75
ECMO, extracorporeal membranous oxygenator; TAVR, transcatheter aortic valve replacement.
Table 2 Prophylactic use of ECMO
Study






Support to  
surgery
Survival to  
discharge (%)
Husser et al. (22) 131 9 (7%) 9 (100%) 0 100
Seco et al. (23) 100 8 (8%) 8 (100%) 0 100
ECMO, extracorporeal membranous oxygenator; TAVR, transcatheter aortic valve replacement.
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comparable with conventional TAVR patients, whereas 
requirement for emergency VA-ECMO was associated with 
significantly lower procedural success and survival. Using of 
ECMO could replace CBP used as prophylaxis in high risk 
patients undergoing TAVR insertion and would be used to 
stabilize patients in cases of hemodynamic instability with 
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